Li Sheng, Niu Zuoxing, Tian He, Zhang Bo, Wang Fangxin, Yi Long-Hai, Yu Jinming
Shandong Tumor Hospital, Jinan, Shandong Province, China.
Hepatogastroenterology. 2007 Jan-Feb;54(73):218-23.
BACKGROUND/AIMS: To investigate the effects of gemcitabine-oxaliplatin in patients with advanced unresectable hepatocellular carcinoma (HCC).
Forty patients confirmed with unresectable, nonembolizable HCC and objective measurable tumors, had received no prior systemic chemotherapy. All patients enrolled in this study had adequate liver and renal functions, and adequate bone marrow reserve. Gemcitabine (1250 mg/m2) was given on day 1 and oxaliplatin (100 mg/m2) on day 2 via intravenous infusion in each 21-day cycle. If no evidence of disease progression or unacceptable adverse effects occurred, the treatment courses would continue.
No affirmative response was achieved; partial response (PR) was achieved in 1 patient. Eight patients (20%) had stable diseases with an average duration of 20.2 weeks. The others were rated progression. The average time to progression was 13.9 weeks. The spectra of both hematologic and nonhematologic toxicities were mild, with thrombocytopenia as the dose-related side effect.
The toxicities of gemcitabine-oxaliplatin were well managed in this study. In view of these treatment results, gemcitabine-oxaliplatin combination therapy with this particular dose regimen should not be considered in patients with advanced hepatocellular carcinoma.
背景/目的：探讨吉西他滨联合奥沙利铂对晚期不可切除肝细胞癌（HCC）患者的疗效。
40例确诊为不可切除、不可栓塞的HCC且有可客观测量肿瘤的患者，此前未接受过全身化疗。本研究纳入的所有患者肝肾功能及骨髓储备均良好。每21天为一个周期，第1天静脉输注吉西他滨（1250mg/m²），第2天静脉输注奥沙利铂（100mg/m²）。若未出现疾病进展迹象或不可接受的不良反应，则继续进行治疗疗程。
未取得肯定性反应；1例患者获得部分缓解（PR）。8例患者（20%）病情稳定，平均持续时间为20.2周。其他患者被评定为病情进展。平均进展时间为13.9周。血液学和非血液学毒性均较轻，血小板减少为剂量相关副作用。
本研究中吉西他滨联合奥沙利铂的毒性得到了良好控制。鉴于这些治疗结果，晚期肝细胞癌患者不应考虑采用该特定剂量方案的吉西他滨联合奥沙利铂治疗。
